Kaléo Inc. said yesterday that its Auvi-Q epinephrine auto-injector will be available by prescription in the U.S. beginning Feb. 14th. The Richmond, Virginia-based company’s emergency allergy treatment was pulled from the market in 2015 due to manufacturing issues.
The Epipen competitor device will be sold at a list price of $4,500, but Kaléo said that as a part of its Auvi-Q AffordAbility program, patients with commercial insurance will pay nothing out-of-pocket. For patients without insurance and a household income of less than $100,000, Auvi-Q will be made available free of charge, according to the company.
Get the full story at our sister site, Drug Delivery Business News.
The post Kaleo announces US availability, pricing of allergy auto-injector appeared first on MassDevice.